Larimar Therapeutics, Inc. logo

Larimar Therapeutics, Inc.

NASDAQ:LRMR

Overview | Financials
Company Name Larimar Therapeutics, Inc.
Symbol LRMR
Currency USD
Price 7.57
Market Cap 483,015,962
Dividend Yield 0%
52-week-range 2.18 - 13.68
Industry Biotechnology
Sector Healthcare
CEO Dr. Carole S. Ben-Maimon M.D.
Website https://www.larimartx.com

An error occurred while fetching data.

About Larimar Therapeutics, Inc.

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company

Related Stocks

IRIDEX Corporation logo

IRIDEX Corporation

IRIX

1.42 USD

Modular Medical, Inc. logo

Modular Medical, Inc.

MODD

2.23 USD

Aspira Women's Health Inc. logo

Aspira Women's Health Inc.

AWH

0.886 USD

Daxor Corporation logo

Daxor Corporation

DXR

9.133 USD

Financials

Numbers are in millions USD

Numbers are in millions USD